Subsequent studies have identified GPX4 as a classical negative regulator of ferroptosis and have roles in various cancers such as clear-cell carcinomas (CCCs), breast cancer, colon cancer (Yang et al., 2014; Seibt et al., 2019; Yang et al., 2020; Lee et al., 2021). Here, GPX4 is linked to cancer.